Disorder clinical trials

Explore recruiting disorder clinical trials.

Recruiting disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)

Spain, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

AMIND - AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized controlled trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

Bulgaria, Austria, Netherlands, Sweden, Belgium, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

Belgium, Bulgaria, Czechia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease

Germany, France, Italy, Belgium, Czechia, Poland +4 more

Phase II and Phase III (Integrated) EU CTIS Study details

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms

Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Disorder trials by city

Disorder in Toronto Disorder in Vancouver Disorder in Montreal Disorder in Calgary Disorder in Edmonton Disorder in Ottawa Disorder in Winnipeg Disorder in Quebec City Disorder in Hamilton Disorder in Kitchener Disorder in London Disorder in Halifax Disorder in New York Disorder in Los Angeles Disorder in Chicago Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease